MERYEM A. ABDESSALEM, SIRIN A. ADHAM^*

Oncology Research, Vol.33, No.1, pp. 27-44, 2025, DOI:10.32604/or.2024.056955 - 20 December 2024

Abstract Nanotechnology in cancer therapy has significantly advanced treatment precision, effectiveness, and safety, improving patient outcomes and personalized care. Engineered smart nanoparticles and cell-based therapies are designed to target tumor cells, precisely sensing the tumor microenvironment (TME) and sparing normal cells. These nanoparticles enhance drug accumulation in tumors by solubilizing insoluble compounds or preventing their degradation, and they can also overcome therapy resistance and deliver multiple drugs simultaneously. Despite these benefits, challenges remain in patient-specific responses and regulatory approvals for cell-based or nanoparticle therapies. Cell-based drug delivery systems (DDSs) that primarily utilize the immune-recognition principle between… More > Graphic Abstract

HUAN GAO^1,2, JIE ZHANG¹, TONY G. KLEIJN^1,3,4, ZHAOYONG WU⁵, BING LIU^1,6, YUJIN MA⁶, BAOYUE DING^1,*, DONGFENG YIN^2,*

Oncology Research, Vol.32, No.4, pp. 769-784, 2024, DOI:10.32604/or.2023.044276 - 20 March 2024

Abstract Bone metastasis secondary to breast cancer negatively impacts patient quality of life and survival. The treatment of bone metastases is challenging since many anticancer drugs are not effectively delivered to the bone to exert a therapeutic effect. To improve the treatment efficacy, we developed Pluronic P123 (P123)-based polymeric micelles dually decorated with alendronate (ALN) and cancer-specific phage protein DMPGTVLP (DP-8) for targeted drug delivery to breast cancer bone metastases. Doxorubicin (DOX) was selected as the anticancer drug and was encapsulated into the hydrophobic core of the micelles with a high drug loading capacity (3.44%). The… More > Graphic Abstract